• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

byYuchen DaiandMichael Pratte
October 12, 2021
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This cohort study found that younger age, spinal cord involvement, and gadolinium-enhancing lesions on magnetic resonance imaging were associated with earlier onset of multiple sclerosis clinical disease in patients with radiologically isolated syndrome.

2. With the widespread use of magnetic resonance imaging technology, early recognition and stratification of associated risk factors of preclinical multiple sclerosis will aid in the prevention of clinical manifestations with subsequent freedom from risk of neurological disability.

Evidence Rating Level: 2 (Good)

Study Rundown: For several decades, preclinical multiple sclerosis (MS) in asymptomatic patients was identified on magnetic resonance imaging (MRI) with findings consistent with central nervous system (CNS) demyelination. This led to the establishment of criteria for radiologically isolated syndrome (RIS) in 2009 to enhance risk stratification in this patient population. However, the clinical and demographic factors associated with time to clinical symptoms of MS among patients with RIS is unclear. This cohort study evaluated the 2-year risk of initial onset of clinical events suggestive of MS and estimated sample sizes needed for 24-month prospective clinical trials based on the primary outcome of a first clinical event. The main endpoint was risk of clinical event, where time to the first clinical event was compared by covariates and sample size estimates were modeled based on identified risk factors. Among 372 patients with RIS, young age, the presence of spinal cord lesions, and gadolinium enhancing lesions on the index MRI scan were associated with increased risk of onset of clinical symptoms of MS. These results identified 3 key preclinical risk factors associated with earlier clinical disease, where MS developed in more than 90% of individuals with 1 or more of these factors. With the widespread use of MRI technology and expansion of access throughout the world, early recognition, and stratification of associated risk factors of preclinical MS will aid in the prevention of clinical manifestations with subsequent freedom from risk of neurological disability. A limitation of this study was that not all patients included in the analysis underwent baseline spinal cord MRI scans and CSF analyses due to differences in regional practice patterns. This could have introduced biases in the analysis and explain why positive CSF findings were not associated with early occurrence of MS.

Click to read the study in JAMA Network Open

Relevant Reading: Radiologically isolated syndrome— incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review

RELATED REPORTS

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis

#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

In-Depth [prospective cohort]: This cohort study included 372 individuals with RIS (mean [SD] age, 38.6 [12.1] years; 354 patients included in analysis [74.6% women]) from a tertiary center for MS care in France that collected data for the Observatoire Français de la Sclérose en Plaques database. Eligible patients were aged 10 to 80 years with 2 or more MRI scans after study entry and an index scan after 2000, with data analysis completed between July 2020 and January 2021. In total, a clinical event occurred in 49 patients (13.8%) within 2 years, equating to an estimated risk of conversion of 19.2% (95%CI, 14.1%-24.0%), where it was determined a total of 160 patients with RIS were needed for 24-month prospective clinical trials. In multivariate analysis, the following factors were independently associated with an increased risk of conversion to MS: age younger than 37 years (HR, 4.04 [95%CI, 2.00-8.15]; P < .001), spinal cord lesions (HR, 5.11 [95%CI, 1.99-13.13]; P = .001), and gadolinium-enhancing lesions on index MRI scan (HR, 2.09 [95%CI, 1.13-3.87]; P = .02). Furthermore, the presence of 2 factors at the time of the index scan was associated with a 27.9% risk (95%CI, 13.5%-39.9%) of a seminal event within 2 years, increasing to 90.9% (95%CI, 41.1%-98.6%) for individuals with all 3 factors (3 risk factors vs none: HR, 23.34 [95%CI, 9.08-59.96]; P < .001), both statistically significant associations.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: multiple sclerosisrelapsing multiple sclerosis
Previous Post

Experience with providing ECMO support may influence COVID-19 related mortality

Next Post

Coffee Industry Must Find New Ways to Stay Afloat

RelatedReports

Chronic Disease

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

June 2, 2025
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis

June 5, 2025
#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis
StudyGraphics

#VisualAbstract: Tolebrutinib Reduced Disaibility Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

May 30, 2025
#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis
StudyGraphics

#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis

April 21, 2025
Next Post

Coffee Industry Must Find New Ways to Stay Afloat

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

Efficacy and safety of therapeutic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19

#VisualAbstract: Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients

#VisualAbstract: Pembrolizumab after nephrectomy improves survival in renal-cell carcinoma patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind July 14, 2025
  • New obesity framework may reclassify over half of overweight individuals as people with obesity
  • Digital health apps may have limited role in reduction of migraine symptoms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.